Literature DB >> 3514463

Characterization of murine monoclonal antibodies to Escherichia coli J5.

K M Miner, C L Manyak, E Williams, J Jackson, M Jewell, M T Gammon, C Ehrenfreund, E Hayes, L T Callahan, H Zweerink.   

Abstract

Twenty-eight independently derived monoclonal antibodies (MAb) directed against Escherichia coli J5 endotoxin were produced and characterized. Each MAb exhibited a specific titer by both radioimmunoassay and passive hemagglutination assay. Most of the MAb were of the immunoglobulin G isotype; however, several immunoglobulin M antibodies and one immunoglobulin A antibody were produced. When characterized for their capacity to cross-react with purified endotoxin preparations from several gram-negative bacteria, 22 MAb exhibited no cross-reactivity; 6 demonstrated a limited capacity to cross-react with other endotoxin preparations. When characterized for their capacity to react with the intact organism instead of the purified endotoxin the pattern of cross-reactivity was quite different. Most of the MAb were able to react with Salmonella minnesota Re595. Eighteen were able to react with E. coli O111:B4 (the parent strain of E. coli J5), 13 MAb reacted weakly with Pseudomonas aeruginosa, and 3 reacted weakly with Klebsiella pneumonia. The data imply that MAb generated against E. coli J5 endotoxin demonstrate greater cross-reactivity when assayed against the whole bacterium than when assayed against the corresponding purified endotoxin. We were unable to demonstrate that any of the 28 MAb could passively protect mice against lethal endotoxin challenge.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514463      PMCID: PMC262197          DOI: 10.1128/iai.52.1.56-62.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Passive immunization against the local Shwartzman reaction.

Authors:  A I Braude; H Douglas
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

2.  Protection against gram-negative infections with antiserum to lipid A from Salmonella minnesota R595.

Authors:  N A Mullan; P M Newsome; P G Cunnington; G H Palmer; M E Wilson
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

3.  Protection against lethality of E. coli endotoxin with "O" antiserum.

Authors:  W J Tate; H Douglas; A I Braude; W W Wells
Journal:  Ann N Y Acad Sci       Date:  1966-06-30       Impact factor: 5.691

4.  Neutralization of toxic bacterial O-antigens with O-antibodies while maintaining their stimulus on non-specific resistance.

Authors:  A Nowotny; R Radvany; N E Neale
Journal:  Life Sci       Date:  1965-05       Impact factor: 5.037

5.  Changing ecology of bacterial infections as related to antibacterial therapy.

Authors:  M Finland
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

6.  A better cell line for making hybridomas secreting specific antibodies.

Authors:  M Shulman; C D Wilde; G Köhler
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

7.  Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli.

Authors:  W R McCabe
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

8.  Recent experience with bacillemia due to gram-negative organisms.

Authors:  R L Myerowitz; A A Medeiros; T F O'Brien
Journal:  J Infect Dis       Date:  1971-09       Impact factor: 5.226

9.  Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

Authors:  M I Marks; E J Ziegler; H Douglas; L B Corbeil; A I Braude
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

10.  Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium.

Authors:  D E Colwell; S M Michalek; D E Briles; E Jirillo; J R McGhee
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

View more
  15 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

Review 2.  Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock.

Authors:  J D Baumgartner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

3.  Characterization of anti-core glycolipid monoclonal antibodies with chemically defined lipopolysaccharides.

Authors:  J de Jongh-Leuvenink; J Schellekens; J Verhoef
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

4.  Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice.

Authors:  S Bailat; D Heumann; D Le Roy; J D Baumgartner; E T Rietschel; M P Glauser; F Di Padova
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

5.  Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time.

Authors:  D E McCallus; N L Norcross
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

7.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity.

Authors:  W C Bogard; D L Dunn; K Abernethy; C Kilgarriff; P C Kung
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

9.  Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.

Authors:  M A Rogy; L L Moldawer; H S Oldenburg; W A Thompson; W J Montegut; S A Stackpole; A Kumar; M A Palladino; M N Marra; S F Lowry
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

10.  Administration in vivo of recombinant interleukin 2 protects mice against septic death.

Authors:  C Weyand; J Goronzy; C G Fathman; P O'Hanley
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.